Farnesoid X receptor agonists as broad-acting antivirals: Evidence from hepatitis viruses and beyond?

IF 4.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Antiviral research Pub Date : 2025-07-01 DOI:10.1016/j.antiviral.2025.106223

Barnault Romain , Vicente-Navarro Inés , Lotteau Vincent , Durantel David , Ramière Christophe

{"title":"Farnesoid X receptor agonists as broad-acting antivirals: Evidence from hepatitis viruses and beyond?","authors":"Barnault Romain , Vicente-Navarro Inés , Lotteau Vincent , Durantel David , Ramière Christophe","doi":"10.1016/j.antiviral.2025.106223","DOIUrl":null,"url":null,"abstract":"<div><div>As intracellular organisms, viruses exploit host metabolism to replicate and propagate. The farnesoid X receptor alpha (FXRα) is a bile acid-activated nuclear receptor that regulates bile acid, glucose and lipid metabolism, as well as inflammation and immunity. Since its discovery in 1995, numerous ligands have been developed to treat metabolism-related syndromes. More recently, FXRα has been shown to modulate the life cycle of various viruses that infect human. This review provides a comprehensive summary of the literature regarding the effect of FXRα agonism in viral infections caused by hepatotropic viruses, enteric viruses and other viral pathogens. Rather than acting through a single antiviral mechanism, FXRα has been reported to influence many steps of viral replication, including entry, transcription and particle secretion. The established safety profiles of FXRα agonists and their clinical use for other pathologies could pave the way for their re-purposing as broad-spectrum antivirals.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"241 ","pages":"Article 106223"},"PeriodicalIF":4.5000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antiviral research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0166354225001494","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

As intracellular organisms, viruses exploit host metabolism to replicate and propagate. The farnesoid X receptor alpha (FXRα) is a bile acid-activated nuclear receptor that regulates bile acid, glucose and lipid metabolism, as well as inflammation and immunity. Since its discovery in 1995, numerous ligands have been developed to treat metabolism-related syndromes. More recently, FXRα has been shown to modulate the life cycle of various viruses that infect human. This review provides a comprehensive summary of the literature regarding the effect of FXRα agonism in viral infections caused by hepatotropic viruses, enteric viruses and other viral pathogens. Rather than acting through a single antiviral mechanism, FXRα has been reported to influence many steps of viral replication, including entry, transcription and particle secretion. The established safety profiles of FXRα agonists and their clinical use for other pathologies could pave the way for their re-purposing as broad-spectrum antivirals.

查看原文本刊更多论文

Farnesoid X受体激动剂作为广谱抗病毒药物：来自肝炎病毒和其他病毒的证据？

作为细胞内生物，病毒利用宿主代谢进行复制和繁殖。farnesoid X受体α (FXRα)是一种胆汁酸激活的核受体，调节胆汁酸、葡萄糖和脂质代谢，以及炎症和免疫。自1995年发现以来，已经开发了许多配体来治疗代谢相关综合征。最近，FXRα已被证明可以调节感染人类的各种病毒的生命周期。本文对FXRα激动作用在嗜肝病毒、肠道病毒和其他病毒病原体引起的病毒感染中的作用进行了综述。据报道，FXRα并不是通过单一的抗病毒机制起作用，而是影响病毒复制的许多步骤，包括进入、转录和颗粒分泌。FXRα激动剂的安全性及其对其他病理的临床应用为其作为广谱抗病毒药物的重新用途铺平了道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antiviral research 医学-病毒学

CiteScore

17.10

自引率

3.90%

发文量

157

审稿时长

34 days

期刊介绍： Antiviral Research is a journal that focuses on various aspects of controlling viral infections in both humans and animals. It is a platform for publishing research reports, short communications, review articles, and commentaries. The journal covers a wide range of topics including antiviral drugs, antibodies, and host-response modifiers. These topics encompass their synthesis, in vitro and in vivo testing, as well as mechanisms of action. Additionally, the journal also publishes studies on the development of new or improved vaccines against viral infections in humans. It delves into assessing the safety of drugs and vaccines, tracking the evolution of drug or vaccine-resistant viruses, and developing effective countermeasures. Another area of interest includes the identification and validation of new drug targets. The journal further explores laboratory animal models of viral diseases, investigates the pathogenesis of viral diseases, and examines the mechanisms by which viruses avoid host immune responses.